No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

MyLab X75 Ultrasound System Launches Reports Esaote: Enriched with Unparalleled Connectivity and Image Sharing Tools

Editor: What To Know

  • Esaote, located in Genoa, Italy mission is to obtain extremely clear, easy-to-read ultrasound images to ensure accurate diagnosis in the shortest time possible, enhancing the users’.
  • MyLab X75 is enriched with unparalleled connectivity and image sharing tools, which clearly facilitate the system management in this challenging pandemic period and allow innovative models to be implemented.
  • Distinguished guests such as the professional alpinist Hervé Barmasse and emeritus medical experts participate in and contribute to the event.

MyLab X75 offers access to specific clinical solutions such as micro-vascularization assessment, liver stiffness quantification as well as zero-click left ventricle function analysis to always deliver the best care possible.

Esaote, located in Genoa, Italy mission is to obtain extremely clear, easy-to-read ultrasound images to ensure accurate diagnosis in the shortest time possible, enhancing the users’ experience across several clinical applications.

“In the world of imaging and non-invasive diagnostics innovation is key,” says Eugenio Biglieri, Esaote COO. “Particularly now that health organizations are under great pressure, ultrasound imaging can give a very important contribution, due to non-ionizing-radiation, agile and point-of-care approach, which ensure accessibility. In this scenario ease of use and automation are the main drivers for the technology’s adoption.”

MyLab X75 is enriched with unparalleled connectivity and image sharing tools, which clearly facilitate the system management in this challenging pandemic period and allow innovative models to be implemented.

“Voice of the customers and consolidated experience were at the core of MyLab X75’s development,” says Giovanni Altobelli, Global Marketing Product Manager, “and making ultrasound imaging easier was our first priority: light and agile, ergonomic and silent, productive and eco-friendly, the new system perfectly meets nowadays clinical needs.”

MyLab X75 is being unveiled on Friday, May 28, 2021 with an exclusive streaming event on several platforms. The event, part of the Esaote’s “Exploring the inside” program, is dedicated to the theme of Experience. Distinguished guests such as the professional alpinist Hervé Barmasse and emeritus medical experts participate in and contribute to the event.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy